Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma × Dexamethasone × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 95 Recurrence 24 Precursor Cell Lymphoblastic Leukemia-Lymphoma 19 Neoplasms, Plasma Cell 11 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8 Neoplasms 8 Immunoglobulin Light-chain Amyloidosis 6 Lymphoma, Non-Hodgkin 5 Lymphoma 5 Leukemia 5 Carcinoma, Non-Small-Cell Lung 5 Amyloidosis 5 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, Mantle-Cell 4 Lymphoma, Large B-Cell, Diffuse 4 Hematologic Neoplasms 4 Burkitt Lymphoma 4 Paraproteinemias 3 Leukemia, Myeloid, Acute 3 Esophageal Neoplasms 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Myelodysplastic Syndromes 2 Meningeal Carcinomatosis 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Follicular 2 Lymphoma, B-Cell 2 Lung Neoplasms 2

Interventions

pembrolizumab 60 Nivolumab 46 Ipilimumab 34 Cyclophosphamide 28 aldesleukin 22 Interleukin-2 19 fludarabine 15 Temozolomide 15 Biopsy 10 trametinib 9 fludarabine phosphate 9 dabrafenib 9 sargramostim 7 Bevacizumab 7 lenvatinib 6 cemiplimab 6 Paclitaxel 6 Dacarbazine 6 Cisplatin 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 Specimen Handling 5 Radiotherapy 5 Magnetic Resonance Spectroscopy 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 epacadostat 4 binimetinib 4 atezolizumab 4 Vemurafenib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡